French pharmaceutical company Ipsen has achieved a significant milestone with the European Commission’s approval of Cabometyx (cabozantinib) for adult patients with unresectable or metastatic, well-differentiated pancreatic (pNET) and extra-pancreatic (epNET) neuroendocrine tumors who have not responded to previous systemic therapy.
Originally developed by Exelixis, Ipsen now holds exclusive rights for commercialization and further clinical development outside the USA and Japan. The drug, which saw sales of 146.9 million euros ($172.9 million) in the first quarter of 2025, has shown promising results in the Phase III CABINET trial, paving the way for improved treatment options in the biotechnology landscape. Register for free to gain access to exclusive features, interviews, and commentary from industry experts in the pharmaceutical and biotechnology sectors, and stay informed with daily updates on the latest biotech and pharma news.
Read more from thepharmaletter.com